Ligand id: 4985

Name: IL-2

Species: Human

IUPHAR Pharmacology Education Project (PEP) logo

View more information in the IUPHAR Pharmacology Education Project: interleukin-2

No information available.
Summary of Clinical Use
Aldesleukin is US FDA approved to treat metastatic renal cell carcinoma. The FDA has also granted orphan designation for non-Hodgkin's lymphoma (1998), primary immunodeficiency disease associated with T-cell defects (1989) and metastatic melanoma (1996). The EMA's orphan designation for renal cell carcinoma was withdrawn by the drug's sponsor.